There are currently 1887 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Thiamine Intervention and Coronary Artery Bypass Grafting
NCT06326996
Recruiting
The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
07/30/2025
Locations: UCLA, Los Angeles, California
Conditions: Coronary Heart Disease, Coronary Artery Bypass Grafting
Register for Updates
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649
Recruiting
The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: California Research Institute, Los Angeles, California
Conditions: Metastatic Colorectal Cancer
Register for Updates
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406
Recruiting
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2025
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +1 locations
Conditions: Metastatic Uveal Melanoma
Register for Updates
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
NCT06654752
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/30/2025
Locations: Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic, Los Angeles, California
Conditions: Cystic Fibrosis
Register for Updates
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919
Recruiting
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: UCLA Medical Center, Los Angeles, California
Conditions: Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
Register for Updates
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT06747858
Recruiting
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Cystic Fibrosis, CFTR Gene Mutation
Register for Updates
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT06882746
Recruiting
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the highest dose for the study medicine called BI 765049 that people with advanced cancer can tolerate. Another purpose is to find the most suitable dose and best way of administration of BI 765049 for furt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California
Conditions: Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
Register for Updates
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320
Recruiting
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2025
Locations: NRC Research Institute DTLA /ID# 267832, Los Angeles, California
Conditions: Generalized Anxiety Disorder (GAD)
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450
Recruiting
The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/30/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Advanced Solid Tumors Cancer, MSI-H Cancer
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: UCLA Clinical Trials Contracts & Strategic Relations, Los Angeles, California +2 locations
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Keck Medicine of USC - Keck Hospital of USC, Los Angeles, California
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Register for Updates